Non-alcoholic Fatty Liver, Obstructive Sleep Apnea
Conditions
Brief summary
Research evaluating the impact of continuous positive airway pressure (CPAP) & walking exercise on fatigue severity, liver enzymes and sleeping quality in patients with non-alcoholic fatty liver disease who also have obstructive sleep apnea. Forty patients are divided into two groups: twenty patients CPAP and other twenty patients for CPAP and walking program .
Detailed description
Research evaluating the impact of continuous positive airway pressure (CPAP) & walking exercise on fatigue severity, liver enzymes and sleeping quality in patients with non-alcoholic fatty liver disease who also have obstructive sleep apnea. Forty patients are divided into two groups: twenty patients CPAP and other twenty patients for CPAP and walking program .
Interventions
BEHAVIORALcontinuous positive airway pressure
continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night
BEHAVIORALfree walking exercise and continuous positive airway pressure
patients will receive continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night. Also, patients will perform walking exercise for 30 mint, daily for 12 weeks
Sponsors
Ahram Canadian University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
The authors of this clinical trial and patients do not provide the study outcome examiners with information regarding device therapy or free walking exercise.
Intervention model description
Forty patients suffering from obstructive sleep apnea are divided into two groups: one for CPAP and the other for CPAP and free walking program.
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* The body mass index (BMI) \< 35 kg/m2. * obstructive sleep apnea patients with fatty liver
Exclusion criteria
* liver transplantation , alcoholic fatty liver, antipsychotic medications, bariatric surgery; cardiac , renal problem , liver cancer ; pregnancy,orthopedic problems, systemic diseases, respiratory dysfunctions, neurological dysfunctions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Alanine tranaminase | it will be measured after 12 weeks | serum hepatic enzyme |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body mass index | it will be measured after 12 weeks | it will be masusured on empty stomach and bladder |
| triglycerodes | it will be assessed after 12 weeks | it will be meausred in plasma |
| Asparatate transamianse | it will be measured after 12 weeks | serum hepatic enzyme |
| fatigue severity scale | it will be assessed after 12 weeks | a questionnaire that wil be used for assessing fatigue |
| Epworth sleepness scale | it will be assessed after 12 weeks | a questionnaire that wil be used for daytime sleepness |
| Pittsiburg sleeping quality index | it will be assessed after 12 weeks | a questionnaire that wil be used for assessing sleeping quality |
Countries
Egypt
Contacts
Backup ContactEl-gohary Ola, PHD
Primary ContactEl-Hadidy Hagar, PHD
Outcome results
None listed